Protein degradation pathway inhibitors

The UPS pathway (ubiquitin proteasome system) is responsible for degradation of proteins in the cell. This pathway malfunctions in many cancer cells, therefore UPS inhibitors can constitute a new therapy used in i.a. cancer of the colon, prostate, lung, breast, in multiple myeloma, B-cell lymphomas, AML. The previously developed therapies, i.a. bortezomib – a proteasome inhibitor, are administered intravenously and are associated with significant adverse effects. Developing a safe, orally-administered inhibitor of protein degradation pathway will constitute a new treatment option for patients with both solid tumours and haematological cancers.